What is TAE Life Sciences?
TAE Life Sciences is at the forefront of developing advanced cancer therapies, specializing in Boron Neutron Capture Therapy (BNCT). This biologically targeted radiotherapy approach is designed to precisely target and eliminate challenging malignancies while minimizing collateral damage to healthy tissues. The company's proprietary Alphabeam Neutron System is central to its mission of enhancing treatment delivery and efficacy. By focusing on therapies that can potentially be administered in a limited number of sessions, TAE Life Sciences aims to revolutionize cancer care and offer more effective options for patients.
How much funding has TAE Life Sciences raised?
TAE Life Sciences has raised a total of $70M across 2 funding rounds:
Series A
$40M
Series B
$30M
Series A (2018): $40M with participation from ARTIS Ventures
Series B (2020): $30M led by ARTIS Ventures
Key Investors in TAE Life Sciences
ARTIS Ventures
Artis Ventures is a dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness. The company aims to create a significant global impact through investments in scalable medical technologies that leverage AI and engineering to develop personalized therapeutics and efficient drug discovery.
What's next for TAE Life Sciences?
The substantial enterprise-level funding TAE Life Sciences has garnered, particularly the recent major strategic investment, positions the company for accelerated growth and further development of its BNCT platform. This capital infusion is expected to fuel advancements in clinical trials, expand operational capacity, and potentially broaden the application of their technology to a wider range of difficult-to-treat cancers. The company's trajectory suggests a strong focus on scaling its innovative treatment solutions and solidifying its market presence in the competitive oncology landscape.
See full TAE Life Sciences company page
